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Summary
Objective: Osteoarthritis (OA) is clinically characterized by degeneration of the joints and has been traditionally considered a primary disorder
of articular cartilage, with secondary changes in the subchondral bone. The increased bone mass and generalized changes in bone quality
observed in osteoarthritic patients suggest that OA may be a primary systemic bone disorder with secondary articular cartilage damage. The
iliac crest is a skeletal site distant from the affected joint, with a minimal load-bearing function. To provide evidence that OA is a systemic
disorder, we searched for differentially expressed genes in the iliac crest bone of patients suffering from hip OA.
Material and methods: Gene expression levels between bone samples collected at surgery from the iliac crest of patients undergoing total hip
arthroplasty for primary OA and younger donors, who were undergoing spinal arthrodesis, were investigated by means of oligonucleotide mi-
croarrays. To verify data detected by microarrays technology, Real Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) assays
were performed with specimens from osteoarthritic patients and donors, as well as from elderly donors who were undergoing arthroplasty for
subcapital femoral neck fracture.
Results: The microarray analysis surveyed 8327 genes and identiﬁed 83 whose expression levels differed at least 1.5-fold in the OA group
(P< 0.005). Comparisons between Real Time RT-PCR data from OA and the two donor groups indicated differential expression of genes
involved in bone cell functions in the group of OA patients. The genes identiﬁed, including CCL2, FOS, PRSS11, DVL2, AKT1, CA2,
BMP6, OMD, MMP2, TGFBR3, FLT1, BMP1 and TNFRS11B, have known roles in osteoblast or osteoclast activities.
Conclusions: The data from this study identify a set of genes, closely related to bone cell functions, in which differential regulation in osteo-
arthritic bone distant from the diseased subchondral bone might underlie the etiopathogenesis of OA as a generalized bone disease.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a disease characterized by joint de-
generation that mainly affects the large weight bearing
joints of the legs, i.e., the hips and knees. Primary OA dif-
fers from secondary forms of the disease, which are due
to trauma, complications of other arthropathies, or endo-
crine or metabolic disorders. OA has traditionally been con-
sidered a primary disorder of articular cartilage, the tissue in
which the initiating events occur, with secondary changes in
the subchondral bone. It is increasingly recognized that
some changes in bone tissues distant from the affected
joints are not easily explained as secondary changes but
may be part of the primary disease process. Thus, an alter-
native hypothesis has recently emerged that postulates that
OA may be a primary systemic bone disorder with second-
ary articular cartilage damage1,2. The increased bone mass*Address correspondence and reprint requests to: N. Vilaboa,
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1106and generalized changes in bone quality observed in oste-
oarthritic patients might alter the mechanical properties of
subchondral bone in weight bearing joints, leading to re-
duced shock absorbance and consequent cartilage
degeneration.
The iliac crest is a skeletal site with high bone turnover
and a minimal load-bearing function. Iliac crests from indi-
viduals suffering from OA show increased high bone den-
sity content, higher cortical thickness, trabecular bone
volume and trabecular width as well as an increased per-
centage of trabecular bone3e5. Levels of bone matrix pro-
teins’ collagen and osteocalcin, or local growth factors
insulin-like growth factor types I and II and transforming
growth factor-beta (TGF-b) increased, while proteoglycan
content diminished in osteoarthritic bone samples from
this skeletal site6,7. Hence, biochemical alterations in this
tissue have been proposed to underlie changes in osteoar-
thritic bone microarchitecture and mechanical properties.
Some genes related to bone turnover have been found to
be differentially expressed in samples from iliac crests of
osteoarthritic and normal donors, supporting the early hy-
pothesis that generalized bone alterations contribute to
1107Osteoarthritis and Cartilage Vol. 17, No. 8the etiopathogenesis of OA8e10. The mRNA levels of sev-
eral genes related to bone homeostasis were signiﬁcantly
altered in the intertrochanteric region of the proximal femur
from patients undergoing hip arthroplasty for primary
OA11e14. This anatomical site is still dependent on stresses
in the proximal femoral shaft. Therefore, we found it of inter-
est to search for unidentiﬁed genes that are differentially ex-
pressed in the iliac crest bone of patients suffering from hip
OA, as minimal stresses can be expected in this location.
Materials and methodsHUMAN BONE SAMPLES COLLECTIONA manual trochar was used to obtain iliac crest biopsies during surgery
from patients undergoing total hip arthroplasty for primary OA (OA group)
or for subcapital femoral neck fracture (elderly or E group). Bone samples
from iliac crest bone grafts were also obtained from patients undergoing spi-
nal arthrodesis due to cervical disc herniation (control or C group). Patients
included in the C and E groups were not affected by OA. Clinical and radio-
graphic criteria reported by Altman et al.15 were used to classify patients with
OA of the hip. Patients included in the OA, C and E groups had not previ-
ously suffered from metabolic diseases that might have affected the skele-
ton. Those cases with a known history of medication that may have
inﬂuenced bone metabolism were excluded from this study. Patients in-
cluded in group E had neither suffered a prior fracture nor had been diag-
nosed with osteoporosis. All individuals included in this study were
Caucasian. Microarray analyses were performed using 6 samples from the
OA group (4 women, 60e77 years old, and 2 men, 64 and 75 years old;
mean age¼ 67.3 7) and 4 samples from the C group (2 women, 32 and
45 years old and 2 men, 43 and 48 years old; mean age¼ 42 6.7). Real
Time RT-PCR analyses were performed using 16 samples from the OA
group (9 women, 57e78 years old and 7 men, 52e75 years old; mean
age¼ 66.9 7.7), 11 samples from the C group (4 women, 32e53 years
old, and 7 men, 26e59 years old; mean age¼ 42.3 11.2) and 8 samples
from the E group (4 women, 84e90 years old, and 4 men, 79e86 years
old; mean age¼ 83.8 4).
Patients enrolled in this research signed an informed consent form and all
procedures were approved by the Human Research Committee of Hospital
Universitario La Paz.RNA PURIFICATIONBone samples were processed immediately after collection to minimize
RNA degradation. Trabecular bone fragments were homogenized with TRI
REAGENT (Molecular Research Center, Inc., Cincinnati, OH, USA) using
an Ultra-Turrax (Ultra-Turrax T8 IKA Werke GMBH & CO. KG, Staufen,
Germany) and total RNA was puriﬁed according to the manufacturer’s
instructions.ANALYSIS OF DIFFERENTIAL GENE EXPRESSION BY
OLIGONUCLEOTIDE MICROARRAYS‘Atlas Plastic Human 8k Microarrays’ (BD Biosciences Clontech, Palo
Alto, CA, USA) were used throughout the study. These include 8327 unique
genes and their corresponding oligonucleotides are gridded in a double-
spotted pattern. Poly(A)þ RNA was puriﬁed from total RNA using oligotex
resin (Qiagen Inc., Valencia, CA, USA) and reverse-transcribed in the pres-
ence of [a-33P]dATP. Puriﬁed radiolabeled probes were hybridized to the mi-
croarrays according to the manufacturer’s instructions. Hybridization signals
were detected by phosphorimager and analyzed using Phoretix array soft-
ware (Nonlinear Dynamics Inc., NUT, UK). Differentially expressed genes
in osteoarthritic patients were identiﬁed using the Student’s t-test
(P< 0.005). The hierarchical clustering method was used to cluster the dif-
ferences in gene expression levels between C and OA groups16. Median
centering and normalization of the data were performed before clustering
and TreeView software was used for visualization.ANALYSIS OF DIFFERENTIAL GENE EXPRESSION BY REAL
TIME RT-PCRComplementary DNAs (cDNAs) were prepared from 1.5 mg of total RNA
using avian myeloblastosis virus reverse transcriptase and random hexam-
ers (Roche Applied Science, Indianapolis, IN, USA). Real Time PCR ampli-
ﬁcations were performed with the TaqMan Low Density Arrays in an ABI
PRISM 7900 HT Sequence Detection System (Applied Biosystems, Foster
City, CA, USA). Two replicates were run for each gene in a 192-well format
plate. Assays were conducted using two independent cDNA preparationsfrom each mRNA sample. Brieﬂy, 50 ml of TaqMan Universal PCR MasterMix
(Applied Biosystems) was mixed with 50 ml of cDNA, corresponding to 50 ng
of total RNA, and applied per channel of the microﬂuidic card. The reaction
mixtures were incubated at 50 C for 2 min, and then at 95 C for 10 min, fol-
lowed by 40 cycles at 95 C (15 s) and 60 C (1 min). Sequence Detector
Software (Applied Biosystems) was used for data analysis. A threshold cycle
(CT) value was determined from a log-linear plot of the PCR signal vs the
cycle number. As CT is an exponential and not a linear term, all data were
converted to the linear form by 2CT determination. The expression of genes
of interest (GI ) was calculated as 2CTGI and then normalized to the endog-
enous reference gene GAPDH (glyceraldehyde-3-phosphate dehydroge-
nase). Among several measured endogenous control genes, we chose
GAPDH for normalization across different genes based on preliminary exper-
iments that indicated that this gene showed the most relatively constant
expression in different samples. One-way analysis of variance with post
hoc Bonferroni was performed to analyze differential expression of genes
between groups of patients. All results were veriﬁed with corresponding
non-parametric tests (ManneWhitney N par t-test). Statistical analyses
were carried out at a P< 0.05 level of signiﬁcance with the Statistical Pack-
age for the Social Sciences, version 11.5 (SPSS Inc, Chicago, IL, USA).
Results
The mRNA levels in six bone samples from the OA group
and four samples from the C group were evaluated by mi-
croarray analysis. Around 500 genes out of 8327 were dif-
ferentially expressed in the OA group as compared to the
C group (P< 0.05) (data not shown). A total of 83 genes
whose expression levels differed at least 1.5-fold between
the C and OA groups were identiﬁed when the statistical
test was carried out at a P< 0.005 level of signiﬁcance.
These genes were then subjected to hierarchical clustering
for visualization. As expected, this analysis clustered data
from the OA and C groups into two separate branches of
the dendrogram (Fig. 1).
To verify data obtained by microarray technology, we per-
formed Real Time RT-PCR assays with a higher number of
specimens from OA patients (n¼ 16) and C donors
(n¼ 11). The mean age of donors included in the C group
was substantially lower than that corresponding to the OA
group. Therefore, it is plausible that genes identiﬁed by mi-
croarray analysis regulate their mRNA levels due to aging
rather than to OA pathology. With the purpose of distin-
guishing those genes speciﬁcally associated with OA and
not to aging-related processes, eight bone samples from
the E group were also included in the Real Time RT-PCR
assays and comparison analyses were performed between
the three groups of samples. The mean age of E group was
substantially higher than that corresponding to the C group,
which ensures that subtle differences in expression levels
of genes up- or down-regulated in aged bone can be clearly
detected. We selected eight up- or down-regulated genes
from the list of differentially expressed genes, including
ﬁve genes with higher (fold changes 1.5 to 3.1; C6orf74,
CCL2, FHL2, PCCA and SH3BP5) and three genes with
lower (fold changes 1.8 to 5.1; FOS, PTGER2 and
SOCS3) expression levels in the OA group than in the C
group (Table I). By means of Real Time RT-PCR, we inves-
tigated expression levels of an additional 15 genes that
were selected from the list of genes detected as differen-
tially expressed in the OA group at a P< 0.05 level of sig-
niﬁcance (ADFP, AKT1, BMP1, DVL2, MMP2, PRSS11,
TGFB2, TGFB3, TNFRSF11B and FLT1). In addition, we
found it of interest to investigate the behavior of ﬁve genes
closely related to bone biology (BMP6, CA2, OMD,
TGFBR1 and TGFBR3) that the microarray analysis failed
to detect as differentially expressed in the C and OA groups
(Table I). A comparison of the expression degree of the 23
selected genes in samples from the group C is shown in
Fig. 2. The results were consistent with microarray data
and conﬁrmed signiﬁcant expression differences between
Fig. 1. Gene array studies. The pattern of expression of 8327 genes was compared in four samples from C group (C1eC4) and six samples
from OA group (OA1eOA6). (Left panel) Hierarchical clustering of 83 human transcripts with differential expression in the OA group
(P< 0.005). The expression data from each sample are represented by a color gradient from red (relative higher expression) to green
(relatively lower expression). Black denotes no change. (Right panel) List of representative genes differentially expressed in the OA group.
Fold changes represent the average change over the four samples from the C group.
Table I
List of genes which relative expression levels were investigated by Real Time RT-PCR assays in C, OA and E bone samples
Symbol Gene name Assay ID
Genes identiﬁed by oligonucleotide microarrays as differentially expressed in OA (P< 0.005)
C6orf74 CGI-130 protein Hs00211409_m1
CCL2 Chemokine (C-C motif) ligand 2 Hs00234140_m1
FHL2 Four and a half LIM domains 2 Hs00179935_m1
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog Hs00170630_m1
PCCA Propionyl Coenzyme A carboxylase, alpha polypeptide Hs00165407_m1
PTGER2 Prostaglandin E receptor 2 (subtype EP2), 53 kDa Hs00168754_m1
SH3BP5 SH3-domain binding protein 5 (BTK-associated) Hs00183137_m1
SOCS3 Suppressor of cytokine signaling 3 Hs00269575_s1
Genes identiﬁed by oligonucleotide microarrays as differentially expressed in OA (P< 0.05)
ADFP Adipose differentiation-related protein Hs00605340_m1
AKT1 v-akt murine thymoma viral oncogene homolog 1 Hs00178289_m1
BMP1 Bone morphogenetic protein 1 Hs00241807_m1
DVL2 Dishevelled, dsh homolog 2 (drosophila) Hs00182901_m1
MMP2 Matrix metalloproteinase 2 (gelatinase A, 72 kDa type IV collagenase) Hs00234422_m1
PRSS11 Protease, serine, 11 (IGF binding) Hs00170197_m1
TGFB2 Transforming growth factor, beta 2 Hs00236092_m1
TGFB3 Transforming growth factor, beta 3 Hs00234245_m1
TNFRSF11B Tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) Hs00171068_m1
FLT1 fms-related tyrosine kinase 1 Hs00176573_m1
Genes not identiﬁed by oligonucleotide microarrays as differentially expressed in OA
BMP6 Bone morphogenetic protein 6 Hs00233470_m1
CA2 Carbonic anhydrase II Hs00163869_m1
OMD Osteomodulin Hs00192325_m1
TGFBR1 Transforming growth factor, beta receptor I Hs00610319_m1
TGFBR3 Transforming growth factor, beta receptor III (betaglycan, 300 kDa) Hs00234259_m1
Endogenous reference gene
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Hs99999905_m1
1109Osteoarthritis and Cartilage Vol. 17, No. 8the C and OA groups (P< 0.05) in six out of eight genes:
FHL2, PCCA, PTGER2, SOCS3, CCL2 and FOS (Figs. 3
and 4). C6orf74 and SH3BP5 showed the predicted higher
expression in bone from OA patients than in C donors, al-
though the expression levels of these genes were not signif-
icantly different (Fig. 5).
ADFP, FHL2, PCCA and TGFB3 mRNA levels were sig-
niﬁcantly higher in OA samples while PTGER2 and SOCS3
were lower, as compared to C samples (Fig. 3). Expression
levels of these genes were not affected by aging, since
there were no signiﬁcant differences between the C and E
groups. No signiﬁcant differences were found after compar-
ison of the OA and E groups. TGFB2 expression increasedAD
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Fig. 2. Relative mRNA expression of 23 selected genes in
trabecular bone samples from the C group (n¼ 11). mRNA levels
were simultaneously analyzed by using TaqMan Low Density
Arrays performed in triplicate and normalized relative to GAPDH
mRNA. The y-axis is logarithmic.in both OA and E samples, as compared to the C group. Al-
though there were no signiﬁcant differences in TGFB2
mRNA levels between the OA and E groups, its expression
might be subjected to a progressive, aging-dependent stim-
ulation, which is not affected by OA disease.
Levels of CCL2 and PRSS11 mRNAs increased and FOS
mRNA decreased in OA patients compared to C donors
(Fig. 4). Comparison of the C and E groups did not reveal
any signiﬁcant differences, suggesting that aged bone
does not modulate the expression of CCL2, FOS and
PRSS11.
CA2 mRNA levels increased, while BMP6 and OMD de-
creased in the E group as compared to the C group. Signif-
icant differences were also detected after comparison
between the OA and E groups (Fig. 5). These data suggest
that CA2, BMP6 and OMD genes modulate their expression
in trabecular bone due to aging while maintaining their
levels in OA. Signiﬁcant differences were detected after
comparing C6orf74, SH3BP5 and TGFBR1 mRNA levels
in the C and E groups, indicating that these genes are sub-
jected to modulation by aging. Despite a lack of signiﬁcant
differences between relative C6orf74, SH3BP5 and
TGFBR1 gene expression in C and OA samples, these
genes followed the same trends as those observed in the
E samples.
Compared to the C group, AKT1 and DVL2 were signiﬁ-
cantly up-regulated, at the mRNA level, in OA samples
(Fig. 6). The E group displayed lower relative gene expres-
sion levels of both genes than the C group. Thus, AKT1 and
DVL2 genes could be subjected to opposite, differential
modulation in OA and E bone samples.
The mRNA levels of a group of genes including MMP2,
TGFBR3, FLT1, BMP1 and TNFRS11B were higher in OA
than in E samples (Fig. 7).
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Fig. 3. Relative expression of ADFP, FHL2, PCCA, PTGER2, TGFB3 and SOCS3 (upper panel) and TGFB2 (lower panel) in trabecular bone
samples from the OA group (n¼ 16), C group (n¼ 11) and E group (n¼ 8). mRNA levels were simultaneously analyzed by using TaqMan
Low Density Arrays, performed in triplicate and normalized relative to GAPDH mRNA. Fold changes are relative to the average expression
level of each gene in samples from the C group, which was given the arbitrary value of 1. Data from the indicated number of samples from
each group were averaged and shown as means S.E.M. *P< 0.05.
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We have identiﬁed a number of genes for which expres-
sion levels are subjected to modulation in samples of oste-
oarthritic trabecular bone collected from the iliac crest. We
selected samples from patients suffering from end-stage
OA, and the observed differences in gene expression could
be, in fact, secondary to the disease. However this is un-
likely, since we have employed bone from a site distant
from the affected joint, having little weight bearing function.
Interestingly, most of the identiﬁed genes have a known or
suspected role in bone biology. The relatively small differ-
ences in expression levels of identiﬁed genes could be ex-
plained on the one hand by the presence of different cell
types in the bone tissue, and on the other hand by the1
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Fig. 4. Relative expression of CCL2, FOS and PRSS11 in
trabecular bone samples from the C, OA and E groups. All
experimental conditions were as in Fig. 3.multifactorial and multigene character of OA that may lead
to subtle expression changes of multiple genes.
Although aging is the risk factor most strongly related to
OA, not all individuals develop OA17,18. To clearly identify
genes that might be modulated as a consequence of aging,
we compared data from younger and elderly groups. As the
prevalence of hip OA increases substantially after age 50
years in both genders, a limitation of our study is that
ages of OA patients are distributed between the age ranges
of younger and elderly groups. Thus, it could be argued that
the genes identiﬁed as differentially modulated in OA bone
could be related to the corresponding intermediate stage of
aging bone. It was reported that the trabecular bone from
iliac crests collected from males and females of about
20e90 years of age showed a progressive reduction in
the collagen content of the bone with increasing age that
paralleled a steady reduction in the mechanical properties
of the bone19. Our data indicate that AKT1 and DVL2
mRNA levels are regulated by age, but follow an opposite
trend in OA samples. On the other hand, CCL2, FOS and
PRSS11 mRNA levels were not affected by aging, but
were clearly deregulated in OA bone. Bearing in mind pro-
gressive changes in bone quality as a function of increasing
age, it does not seem plausible that differences observed in
the gene expression in OA group could be regarded as only
a function of age.
PRSS11, FOS and CCL2 mRNA levels were not modu-
lated in aged bone, but were differentially regulated in
bone from osteoarthritic patients. PRSS11 encodes a se-
creted protease and its gene expression, both at the
mRNA and at the protein levels, is elevated in the joint
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Fig. 5. Relative expression of BMP6, CA2, C6ORF74, OMD, SH3BP5 and TGFBR1 in trabecular bone samples from the C, OA and E groups.
All experimental conditions were as in Fig. 3.
1111Osteoarthritis and Cartilage Vol. 17, No. 8cartilage of human osteoarthritic patients20. Murine Prss11
is also expressed in the matrix of bone trabeculae and the
cortex21. Its production has been attributed to osteoblasts
at the late differentiation stages and mature osteocytes em-
bedded in bone21. Murine PRSS11 activity inhibits TGF-
b signaling22 and levels of TGF-b1 and TGF-b2 proteins
are higher in osteoarthritic bone samples from anatomical
sites distant from the affected joint9. Therefore, higher
PRSS11 gene expression might operate as a compensatory
mechanism in this disease to modulate the levels of these
growth factors through its proteolytic activity. FOS encodes
C-FOS, a component of the dimeric transcription factor ac-
tivator protein-1 that regulates osteoclast-speciﬁc gene ex-
pression. Alterations in bone turnover and osteoclast
functions are recognized as important elements that may
contribute to biochemical and structural changes in sub-
chondral bone during the pathogenesis of OA23,24. Mice
lacking Fos develop osteopetrosis due to a complete block
in osteoclast differentiation25,26. Osteopetrosis comprises
a heterogeneous group of rare genetic disorders character-
ized by increased skeletal mass due to overall defects in
osteoclast function27,28. Interestingly, patients with osteo-
petrosis are at risk for OA29, supporting the relationship
between increased bone mass and the risk of developing
OA. Thus, lower FOS expression in osteoarthritic bone1
2
3
AKT1 DVL2
* *
*
* *
*
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n
le
ve
ls
C
OA
E
Fig. 6. Relative expression of AKT1 and DVL2 in trabecular bone
samples from the C, OA and E groups. All experimental conditions
were as in Fig. 3.could reﬂect systemic, decreased osteoclast activity.
CCL2 is a member of the CC chemokine subfamily, which
regulates monocyte chemotaxis in bone tissues30. CCL2
is involved in tooth eruption as well as in the bone degrada-
tion observed in rheumatoid arthritis, bacterially induced
osteomyelitis and periprosthetic osteolysis31e34. Increased
levels of CCL2 do not always correlate with monocyte
inﬂux, suggesting other biological activities for CCL2. For
example, CCL2 stimulates collagen and TGFB1 expression
in ﬁbroblasts35. It remains to be proven whether higher
CCL2 expression in the iliac crest bone of osteoarthritic
patients accounts for the increased levels of those proteins
detected in this tissue6,7.
DVL2 belongs to the Dishevelled family of proteins, which
are pivotal intracellular transducers of the wingless-int, sig-
naling pathway. WNT/b-catenin signaling regulates bone
mass by promoting osteogenesis through multiple mecha-
nisms36. Thus, the decreased DVL2 mRNA levels in aged
bone could reﬂect a down-regulation of the WNT signaling
pathway that contributes to diminished bone mass. On the
other hand, this pathway might be up-regulated in osteoar-
thritic bone distant from the diseased site. Interestingly, it
has recently been reported that the expression of several
other genes related to the WNT signaling is deregulated
in the trabecular bone of the proximal femur of patients af-
fected by primary OA of the hip13. As observed for DVL2,
AKT1 mRNA was up-regulated in OA samples and down-
regulated in E samples, as compared to C samples. AKT1
is one of the three isoforms of the AKT protein, also known
as protein kinase B, which plays an essential role in promot-
ing cell proliferation and preventing apoptosis37,38. Thus,
lower expression of AKT1 might account for loss of bone
mass during aging, while increased AKT1 mRNA levels in
osteoarthritic bone would operate in an opposite fashion. In-
terestingly, murine AKT has been shown to act in associa-
tion with DVL to prolong the survival of osteoblasts and
uncommitted osteoblast progenitors39,40.
Comparison analyses between younger and elderly do-
nors groups indicate that CA2, Bmp6 and OMD genes might
be subjected to regulation during bone aging. In vitro exper-
iments indicate that BMP6 is a potent inducer of osteoblast
differentiation of mesenchymal cells41. Bmp6 mRNA levels
are reduced in the femur of aged ovariectomized rats, com-
pared to sham controls42. Interestingly, systemic administra-
tion of BMP6 greatly restores bone loss and improves the
bone quality of osteoporotic rats42. Semiquantitative RT-
PCR assays performed in human iliac crests failed to detect
any change in BMP6 expression related to age10. However,
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Fig. 7. Relative expression of BMP1, MMP2, FLT1, TGFBR3, and TNFRS11B in trabecular bone samples from the C, OA and E groups.
All experimental conditions were as in Fig. 3.
1112 E. Sa´nchez-Sabate´ et al.: Gene expression in osteoarthritic trabecular bonewe detected a signiﬁcant decrease in human trabecular bone
from aged subjects bymeans of Real Time RT-PCR analysis
and,more relevant to the present investigation, that this gene
is not subjected to down-regulation in osteoarthritic bone.
OMD expression followed the same trend as BMP6. OMD
encodes osteomodulin, a minor proteoglycan found in the
mineralized matrix of bone, where it binds to hydroxyapa-
tite43. It is expressed in mature osteoblasts located superﬁ-
cially on trabecular bone and has been proposed as an
organizer of mineral formation44. Thus, maintenance of
OMD expressionmay account for mineralization changes re-
ported in osteoarthritic trabecular bone from anatomical sites
distant from the affected joints3,4. The CA2 gene encodes
carbonic anhydrase II, an abundant enzyme located in the
osteoclast cytoplasm and on the inner surface of its rufﬂer
border. This enzyme catalyzes the interconversion of CO2
and water to HCO3
 and protons, and plays a key role in
the bone resorptive activity of mature osteoclasts. CA2 ex-
pression is higher in active, resorbing mature osteoclasts
than in non-active osteoclasts45. CA2 mRNA increased in
bone samples from aged donors, compared to those from
younger donors, which may reﬂect the net increase in osteo-
clast population and resorption activity that result in bone
loss during aging46.CA2 deﬁciency results in an intermediate
form of osteopetrosis47,48. It remains to be shown whether
maintenance inCA2 expression levels in osteoarthritic tissue
contributes to the greater bone mass characteristic of the
disease49.
A group of six genes including ADFP, FHL2, PCCA,
PTGER2, TGFB3 and SOCS3 did not show any signiﬁcant
age-related difference but were identiﬁed as differentially
regulated in osteoarthritic samples. The lack of signiﬁcant
differences between expression levels in samples from os-
teoarthritic and elderly samples does not allow us to unam-
biguously identify these genes as associated with OA.
However, some of these genes might play a role in the dis-
ease. ADFP encodes a protein marker of lipid accumula-
tion. Initially described in adipocytes, ADFP protein is
a lipid droplet-associated protein present in a variety of cells
such as ﬁbroblasts and macrophages50. ADFP overexpres-
sion in macrophages increases the size of lipid droplets by
stimulating the incorporation of fatty acyl-CoAs into triglyc-
erides and by inhibiting fatty acid oxidation51. We also de-
tected an increase in PCCA mRNA levels in osteoarthritic
bone samples. PCCA encodes the alpha subunit of the het-
erodimeric mitochondrial enzyme propionyl-CoA carboxyl-
ase. Trabecular bone from femoral heads of osteoarthritic
patients contains high levels of fat and fatty acids52. Al-
though the roles of ADFP and PCCA on bone remodeling
have not yet been established, up-regulation of these genesin osteoarthritic bone supports earlier hypotheses claiming
that changes in lipid metabolism might underlie a systemic
disorder53. FHL2 overexpression increases osteoblast pro-
liferation and maturation as well as matrix mineraliza-
tion54,55. SOCS3, a member of the cytokine signaling
suppressor family, has recently been proposed as a critical
regulator of bone remodeling by modulating osteoclasto-
genesis56. TGFB2 was identiﬁed as an up-regulated gene
in both the osteoarthritic and the elderly groups. Transgenic
mice expressing high levels of the murine homolog gene in
osteoblasts exhibit defective bone mineralization, which
leads to an age-dependent loss of bone mass57.
Finally, we identiﬁed a group of genes, including BMP1,
FLT1, MMP2, TGFBR3, and TNFRSF11B, for which
mRNA levels are signiﬁcantly higher in osteoarthritic bone
than in samples from aged donors. Through cleaving of
the latent TGF-binding protein, BMP1 cooperates in
TGFB1 activation, an inducer of the osteoblast pheno-
type58. Higher levels of TGFB1 protein have been found
in OA bone samples9. It remains to be investigated whether
there is a correlation between levels of TGFB1 and BMP1
activity in OA samples that might operate to promote oste-
oblast differentiation and bone mass. BMP1 also plays an
essential role in regulating the formation of the bone extra-
cellular matrix by promoting cleavage of the propeptides of
the major ﬁbrillar collagens59. Subchondral bone as well as
bone tissue close to the femoral neck from patients suffer-
ing from OA of the hip exhibits greater collagen deposition,
compared with normal specimens60. Thus, higher BMP1 ex-
pression might contribute to systemic, increased bone colla-
gen matrix formation in the disease. On the other hand,
relatively higher MMP2 expression in osteoarthritic bone
could operate in an opposite fashion resulting in higher
rates of collagen turnover. In fact, high levels of pro and ac-
tive MMP2 protein content have been detected in bone tis-
sue of diseased joints60. The expression of TNFRS11B that
encodes the secreted factor osteoprotegerin, a decoy re-
ceptor for receptor activator for nuclear factor k B ligand
or RANKL, was also lower in aged bone from donors than
in osteoarthritic patients. Osteoprotegerin inhibits the differ-
entiation, survival, and fusion of osteoclastic precursor
cells, suppresses osteoclast activation, and promotes oste-
oclast apoptosis61. Murine Tnfrs11b expression has been
shown to decline in bone during aging62, a mechanism
that does not seem to operate in bone from osteoarthritic
patients. FLT1 encodes the vascular endothelial growth fac-
tor receptor 1 (VEGFR1) and its expression has been re-
ported in bone cell types including osteoblasts and
osteoclasts63e65. It has recently been reported that trabec-
ular bone volume and trabeculae number were reduced,
1113Osteoarthritis and Cartilage Vol. 17, No. 8while trabecular separation increased, in mice lacking the
intracellular tyrosine kinase domain of the murine Flt1
gene, compared with age-matched wild-type mice66. Data
in our study are suggestive of modulation for this receptor
expression during aging, since they reveal relatively low
levels of FLT1 mRNA in E bone compared to OA samples.
TGFBR3, also known as betaglycan, functions by binding
TGF-b via its core protein and then transferring the growth
factor to its signaling receptor, the type II receptor67,68. Ac-
cording to our data, TGFBR3 expression at the mRNA level
is higher in the iliac crest of osteoarthritic samples than in
aged donors, suggesting a role for this gene in altered
TGF-b signaling in the disease.
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